What C4X does
To achieve this goal it is using cutting-edge technologies and expertise to efficiently deliver small-molecule (pharmaceutical) medicines.
It has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental data.
This enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.
Unlike many drug companies, it looks to find partners at the pre-clinical phase, allowing big pharma to fund expensive human trials.
It successfully out-licensed its programme for addictive disorders to Indivior, receiving an upfront £7.7mln (US$10mln) and milestones of £227mln (US$294mln).
It is working on potential treatments for Parkinson’s, Alzheimer’s and inflammatory bowel disorders and it has numerous collaboration deals.
Below is the company’s drug pipeline
How it is doing
FTSE 250-listed drug group Indivior has taken C4X’s treatment for opioid use disorder into the clinic as part of a deal worth US$294mln. Phase I and II studies will receive financial backing from the National Institutes of Health in the US.
C4X also began a new partnership with the GEN-COVID Consortium in Italy to deploy C4X’s Taxonomy3 platform technology to examine genetic data from COVID-19 patients to identify genes specifically associated with severe types of the disease.
A phase I, single ascending dose trial of the company’s Orexin-1 antagonist, C4X_3256, should be completed by the end of the year.
Meanwhile, its most advanced in-house programmes, NRF-2 and IL-17, continue to move forward: one of C4X’s lead NRF-2 molecules, C4X_6746, has shown significant efficacy in a pre-clinical model of inflammatory bowel disease (IBD)
What the boss says: Clive Dix, chief executive
“The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis."
“This is a new area for C4XD and we are excited to be working on such an important project," he commented on the project with GEN-COVID Consortium.
- Clinical trial for the Orexin-1 programme with Indivior
- A partner for the NRF-2 activator programme with the company seeing commercial interest
- Partnership with the GEN-COVID Consortium for COVID-19 patients